Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
The MNK news page on Stock Titan aggregates company-issued updates and media coverage related to Mallinckrodt plc and its subsequent branded therapeutics identity, Keenova Therapeutics. Recent press releases describe Mallinckrodt as a global specialty pharmaceutical company with a Brands business focused on autoimmune and rare diseases and a Par Health business that includes generic drugs, sterile injectables and active pharmaceutical ingredients.
News items for MNK include announcements on corporate transactions, such as the completion of the merger between Mallinckrodt and Endo, Inc., and the spin-off of the combined generics and sterile injectables businesses under the Par Health name. These releases also explain that, moving ahead, Mallinckrodt will be known as Keenova Therapeutics, a branded therapeutics company focused on helping patients with rare or unaddressed conditions.
Investors and followers of MNK can find updates on financial results, including quarterly net sales and segment performance for Specialty Brands, Generics and Sterile Injectables as reported by the company. Other news covers developments in key branded products, such as Acthar Gel and XIAFLEX, as well as communications about clinical and medical affairs activities, including data presentations related to TERLIVAZ for hepatorenal syndrome.
Additional coverage includes leadership and governance announcements, such as board appointments and executive changes, along with guidance and commentary on the company’s strategy around its Brands and Par Health businesses. For users tracking MNK, this news feed provides a central view of the company’s own disclosures on its therapeutic focus, portfolio evolution, corporate structure and branded transition to Keenova Therapeutics.
Mallinckrodt (NYSE:MNK) and Endo have completed their merger to create a global therapeutics leader. Under the deal terms, Endo shareholders received $100 million in cash and will own 49.9% of Mallinckrodt, while pre-transaction Mallinckrodt shareholders retain 50.1% ownership.
The merger includes plans to spin off their combined generics and sterile injectables business (Par Health) as an independent company by Q4 2025. The company expects to achieve $150 million in annual pre-tax synergies by Year 3, with $75 million in the first year. A $1.35 billion secured credit facility was established to refinance debt and fund the transaction.
Post spin-off, the branded therapeutics company will seek NYSE listing. Siggi Olafsson continues as CEO, with Paul Efron serving as Board Chair of the combined entity.
Mallinckrodt (NYSE:MNK), a global specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025. The company will host an investor conference call at 8:30 a.m. ET.
Investors can participate through multiple channels, including a live dial-in registration system and an audio-only webcast. The presentation will also be accessible through Mallinckrodt's Investor Relations website.
Mallinckrodt (MNK) and Endo (OTCQX: NDOI) have made significant progress towards their proposed merger announced in March 2025. Key developments include: S-4 registration statement becoming effective, expiration of HSR waiting period, and Irish High Court approval for shareholder meetings. Both companies have scheduled shareholder votes for June 13, 2025.
The merger plan includes spinning off the combined generic pharmaceuticals and Endo's sterile injectables business into a separate entity from the branded pharmaceuticals business. Post-merger, Mallinckrodt shareholders will own 50.1% of the combined company, while Endo shareholders will receive $80 million in cash and own 49.9%. The deal is expected to close in H2 2025, with Dublin, Ireland serving as global headquarters.
Acthar Gel sales increased 12.3% to $115.4 million, marking its fifth consecutive quarter of growth. The SelfJect device now accounts for >70% of new prescriptions. INOmax EVOLVE DS delivery system is now in over 50 hospitals with 400+ systems placed.
The company's cash balance stood at $422.2 million, with total debt reduced by 47.5% YoY to $864.6 million. Mallinckrodt reaffirmed its 2025 guidance with expected net sales of $1.7-1.8 billion and Adjusted EBITDA of $480-520 million. The company is progressing toward completing its merger with Endo in H2 2025.
Mallinckrodt has announced the presentation of five clinical studies on TERLIVAZ® (terlipressin) at the 2025 Digestive Disease Week (DDW) in San Diego. The research focuses on treating hepatorenal syndrome (HRS) with rapid reduction in kidney function, also known as HRS-AKI.
TERLIVAZ is the first FDA-approved treatment for this rare condition, which affects over 42,000 Americans annually (0.01% of U.S. population). The presentations include one oral presentation and four posters, covering topics such as real-world treatment outcomes, comparative analysis between UK and US patients, and efficacy in patients with alcohol-associated liver disease.
The presentations will take place from May 3-6, 2025, featuring research on transplant waitlist status, treatment comparisons, and benefit-to-risk profiles. Important safety information indicates that TERLIVAZ may cause serious respiratory failure, particularly in patients with volume overload or acute-on-chronic liver failure Grade 3.
Mallinckrodt (MNK) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025. The global specialty pharmaceutical company will host an investor conference call at 8:30 a.m. ET on the same day.
Investors can participate through multiple channels, including a live call registration system, an audio-only webcast, or through the company's Investor Relations webpage.
Mallinckrodt reported strong financial results for Q4 and FY 2024, achieving the high end of full-year net sales guidance. Full-year net sales grew 6.1% to $2.0 billion, with Acthar® Gel growing 14.2% and Specialty Generics up 15.4%. The company reduced total debt by 47% and net debt by 64%.
Q4 2024 net sales reached $492.1 million, up 4.9% from Q4 2023. The Specialty Brands segment reported $265.6 million in net sales, while Specialty Generics achieved $226.5 million. Q4 net income was $612.8 million, with Adjusted EBITDA at $124.2 million.
For 2025, Mallinckrodt expects net sales between $1.7-1.8 billion and Adjusted EBITDA of $480-520 million. The company's performance was driven by Acthar Gel's successful SelfJect™ device launch and accelerated uptake of INOmax® EVOLVE™ DS delivery system.